Accuray Incorporated Earnings Recaps
Q1 2027
Nov 9, 2026
Accuray’s shares fell 16.9% after the company said first-quarter product orders and revenue missed its own expectations, with geopolitical and other market factors in China weighing on product sales. The transcript points to product performance—notwithstanding improvements in service—as the main disappointment.
Key takeaways
- Management said product orders and revenue did not meet expectations; China was a key headwind.
- Service revenue increased and service margins improved, while operating expenses remained well controlled.
- The company said its installed base continued to expand, supporting recurring service revenue.
- Accuray announced a RaySearch agreement to advance online adaptive radiation therapy, initially on Radixact, and progressed its Samsung NeuroLogica collaboration on CyberKnife imaging.
- Management’s stated priority is converting its pipeline and customer interest into orders and product revenue; the excerpt provides no updated financial guidance.